A Study of NTX-1472 in Social Anxiety Disorder

Conditions

• Social Anxiety Disorder (SAD)

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• NTX-1472 — DRUG
  Daily (QD) x 8 weeks.
• Placebo — DRUG
  Daily (QD) x 8 weeks.

Study Details

The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests

Key Dates

Start date

Dec 9, 2025

Status verified

Jan 2026

Primary completion

Jan 31, 2027

Completion

Jan 31, 2027

Study Design

Enrollment

100 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: NTX-1472
• Placebo Comparator: Placebo

Primary Outcome Measure

Incidence and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline to Week 8 ]

Central Contacts

• Newleos Therapeutics Clinical Trial Team
  978-780-5937
  [email protected]

Locations (11)

Find similar trials in Pheonix, AZ

Related Studies

• Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
  PHASE3 · Recruiting · Vanda Pharmaceuticals · Phoenix, Arizona
• Stepped Care Treatment for Anxiety Resilience
  Recruiting · Andrew Wiese · Houston, Texas